| Y/e 31 Mar | Mar-2022 | Mar-2021 | Mar-2020 | Mar-2018 |
|---|---|---|---|---|
Growth matrix (%) | ||||
Revenue growth | 15.39 | 2.01 | 23.96 | -16.11 |
Op profit growth | 20.97 | 21.41 | 24.35 | -44.41 |
EBIT growth | 26.61 | 30.03 | 12.65 | -47.63 |
Net profit growth | 12.7 | -22.87 | 74.17 | -68.96 |
Profitability ratios (%) | ||||
OPM | 26.5 | 25.27 | 21.23 | 21.17 |
EBIT margin | 23.73 | 21.63 | 16.97 | 18.67 |
Net profit margin | 8.46 | 8.66 | 11.46 | 8.16 |
RoCE | 16.91 | 12.82 | 9.95 | 9.46 |
RoNW | 1.73 | 1.58 | 2.25 | 1.44 |
RoA | 1.5 | 1.28 | 1.68 | 1.03 |
Per share ratios (₹) | ||||
EPS | 14.2 | 9.52 | 17.45 | 10.7 |
Dividend per share | 10 | 7.5 | 4 | 2 |
Cash EPS | 4.7 | 3.43 | 7.13 | 2.75 |
Book value per share | 200.1 | 193.64 | 188.65 | 159.69 |
Valuation ratios | ||||
P/E | 64.42 | 62.77 | 20.18 | 46.29 |
P/CEPS | 194.41 | 174.03 | 49.35 | 179.62 |
P/B | 4.57 | 3.08 | 1.86 | 3.1 |
EV/EBIDTA | 19.06 | 15.09 | 11.32 | 18.5 |
Payout (%) | ||||
Dividend payout | 0 | 0 | 0 | 22.19 |
Tax payout | -11.88 | -7.24 | -15.61 | -19.08 |
Liquidity ratios | ||||
Debtor days | 92.28 | 100.69 | 95.79 | 103.46 |
Inventory days | 84.61 | 91.91 | 82 | 94.47 |
Creditor days | -60.39 | -58.15 | -62.41 | -85.38 |
Leverage ratios | ||||
Interest coverage | -72.04 | -51.24 | -18.4 | -9.55 |
Net debt / equity | -0.07 | -0.05 | 0.04 | 0.01 |
Net debt / op. profit | -0.36 | -0.3 | 0.26 | 0.08 |
Cost breakup (₹) | ||||
Material costs | -26.77 | -25.94 | -28.1 | -28.02 |
Employee costs | -18.88 | -20.48 | -19.37 | -20.26 |
Other costs | -27.83 | -28.29 | -31.27 | -30.53 |
Based on the Phase 2b clinical trial, the study used a randomised, double-blind, placebo-controlled design that yielded strong and dependable data.
The deal is expected to be completed in the second quarter of 2025, subject to customary closing conditions and regulatory approvals.
An interim dividend of ₹10.50 on the face value per share for FY25 has been declared.
Sun Pharma has bolstered its speciality pipeline with a partnership with Philogen to commercialise late-stage candidate Fibromun.
The US Food and Drug Administration (USFDA) has approved LEQSELVI (deuruxolitinib) 8 mg tablets, according to a regulatory filing.
IMVEXXY is a vaginal insert designed to lessen pain during sexual activity after menopause which is manufactured by Mayne Pharma.
The warning letter detailed substantial violations of Current Good Manufacturing Practice (CGMP) regulations for finished pharmaceuticals at the facility.
Invest wise with Expert advice
IIFL Customer Care Number
(Gold/NCD/NBFC/Insurance/NPS)
1860-267-3000 / 7039-050-000
IIFL Capital Services Support WhatsApp Number
+91 9892691696
Download The App Now
Follow us on
2025, IIFL Capital Services Ltd. All Rights Reserved
IIFL Capital Services Limited - Stock Broker SEBI Regn. No: INZ000164132, PMS SEBI Regn. No: INP000002213,IA SEBI Regn. No: INA000000623, SEBI RA Regn. No: INH000000248
ARN NO : 47791 (AMFI Registered Mutual Fund Distributor)
This Certificate Demonstrates That IIFL As An Organization Has Defined And Put In Place Best-Practice Information Security Processes.
